Update on New Antiepileptic Drugs in Children

Primary Psychiatry

Volumn 11, Issue 4, 2004, Pages 40-45

  Leary, Linda D ^a,b   Morrell, Martha J ^a  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b Internal Medicine New York Presbyterian   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; ETHOSUXIMIDE; ETIRACETAM; FELBAMATE; GABAPENTIN; LAMOTRIGINE; OXCARBAZEPINE; PHENOBARBITAL; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROATE SEMISODIUM; VALPROIC ACID; VOLTAGE GATED CALCIUM CHANNEL; ZONISAMIDE;

CHILD; DOSE RESPONSE; DRUG ELIMINATION; DRUG SAFETY; DRUG TOLERABILITY; EPILEPSY; HUMAN; LIVER METABOLISM; MENTAL DISEASE; PSYCHIATRIC DIAGNOSIS; REVIEW; VAGUS NERVE STIMULATION;

EID: 2342505814     PISSN: 10826319     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (64)

1. Fisher RS. Update on the mechanisms of action of the new antiepileptic drugs. Paper presented at: Merritt-Putnam Lectures, Update on Epilepsy Management and Emerging Uses of Antiepileptic Drugs; June 27, 1998; San Francisco, CA.
2. McNamara JO. Drugs effective in the therapy of the epilepsies. In: Hardman JG, Limbird LE, Molinoff PB, Ruddon RW, Goodman Gilman A, eds. Goodman & Gilman's The Pharmacological Basis of Therapeutics. 9th ed. New York, NY: McGraw-Hill, Health Professions Division; 1996:461-486.
3. Leniger T, Wiemann M, Bingmann D, Widman G, Hufnagel A, Bonnet U. Carbonic anhydrase inhibitor sulthiame reduces intracellular pH and epileptiform activity in hippocampal CA3 neurons. Epilepsia. 2002;43(5):469-474.
4. Bazil CW. Antiepileptic drugs in the 21st century. CNS Spectr. 2001;6(9):756-762.
5. A receptors. Ann Neurol. 1994;35(2):229-234.
6. Glauser TA. Idiosyncratic reactions: new methods of identifying high-risk patients. Epilepsia. 2000;41(suppl 8):S16-S29.
7. Pellock JM. Felbamate. Epilepsia. 1999;40(suppl 5):S57-S62.
8. Pellock JM. Felbamate in epilepsy therapy: evaluating the risks. Drug Saf. 1999;21(3):225-239.
9. French J, Smith M, Faught E, Brown L. Practice advisory: the use of felbamate in the treatment of patients with intractable epilepsy. Epilepsia. 1999;40(6):803-808.
10. French J, Smith M, Faught E, Brown L. Practice advisory: The use of felbamate in the treatment of patients with intractable epilepsy: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Epilepsy Society. Neurology. 1999;52(8):1540-1545.
11. Benedetti S. Enzyme induction and inhibition by new antiepileptic drugs: a review of human studies. Fundam Clin Pharmacol. 2000;14(4):301-319.
12. Anderson GD. A mechanistic approach to antiepileptic drug interactions. Ann Pharmacother. 1998;32(5):554-563.
13. Wheless JW. Treatment strategies in pediatric epilepsy: pharmacological treatment. Paper presented at: Annual Meeting of the American Epilepsy Society; December 2, 2000; Los Angeles, CA.
14. Luo ZD, Calcutt NA, Higuera ES, et al. Injury type-specific calcium channel alpha 2 delta-1 subunit up-regulation in rat neuropathic pain models correlate with antiallodynic effects of gabapentin. J Pharmacol Exp Ther. 2002;303(3):1199-1205.
15. Herranz JL. Gabapentin: its mechanism of action in the year 2003 [Spanish]. Rev Neurol. 2003;36(12):1159-1165.
16. Genton P. When antiepileptic drugs aggravate epilepsy. Brain Dev. 2000;22(2):75-80.
17. Perucca E, Gram L, Avanzini G, Dulac O. Antiepileptic drugs as a cause of worsening seizures. Epilepsia. 1998;39(1):5-17.
18. Blanco C, Raza MS, Schneier FR. Liebowitz MR. The evidence-based pharmacological treatment of social anxiety disorder. Int J Neuropsychopharmacol 2003;6(4):427-442.
19. Blanco C, Schneier FR, Schmidt A, et al. Pharmacological treatment of social anxiety disorder: a meta-analysis. Depress Anxiety. 2003;18(1):29-40.
20. Besag FM. Behavioural effects of the newer antiepileptic drugs: an update. Expert Opin Drug Saf. 2004;3(1):1-8.
21. Neurontin [package insert]. New York, NY: Pfizer Inc.; 2003.
22. McLean MJ, Gidal BE. Gabapentin dosing in the treatment of epilepsy. Clin Ther. 2003;25(5):1382-1406.
23. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43(suppl 3):53-59.
24. Gilliam F, Vazquez B, Sackellares JC, et al. An active-control trial of lamotrigine monotherapy for partial seizures. Neurology. 1998;51(4):1018-1025.
25. Choi H, Morrell MJ. Review of lamotrigine and its clinical applications in epilepsy. Expert Opin Pharmacother. 2003;4(2):243-251.
26. Buchanan N. The use of lamotrigine in juvenile myoclonic epilepsy. Seizure. 1996;5(2):149-151.
27. Guberman AH, Besag FM, Brodie MJ, et al. Lamotrigine-associated rash: risk/benefit considerations in adults and children. Epilepsia. 1999;40(7):985-991.
28. Feliciani C, Verrotti A, Coscione G, et al. Skin reactions due to anti-epileptic drugs: several case-reports with long-term follow-up. Int J Immunopathol Pharmacol. 2003;16(1):89-93.
29. Hirsch LJ, Claassen J, Spencer HT, et al. Predicting rash from lamotrigine: results from review of 812 patients. Epilepsia. 2003;44(suppl 9):277.
30. Green B. Lamotrigine in mood disorders. Curr Med Res Opin. 2003;19(4):272-277.
31. Aldenkamp AP, Baker G, Mulder OG, et al. A multicenter, randomized clinical study to evaluate the effect on cognitive function of topiramate compared with valproate as add-on therapy to carbamazepine in patients with partial-onset seizures. Epilepsia. 2000;41(9):1167-1178.
32. Jones MW. Topiramate - safety and tolerability. Can J Neurol Sci. 1998;25(suppl 3):S13-S15.
33. Gerber PE, Hamiwka L, Connolly MB, Farrell K. Factors associated with behavioral and cognitive abnormalities in children receiving topiramate. Pediatr Neurol. 2000;22(3):200-203.
34. Dooley JM, Camfield PR, Smith E, Langevin P, Ronen G. Topiramate in intractable childhood onset epilepsy - a cautionary note. Can J Neurol Sci. 1999;26(4):271-273.
35. Topamax [package insert]. Raritan, NJ: Ortho-McNeil Pharmaceutical, Inc. ; 2003.
36. Shields DW, Wu SC. Safety of topiramate (TPM) in children with epilepsy [abstract]. Epilepsia. 1999;40(suppl 7):126.
37. Ben-Zeev B, Watemberg N, Augarten A, et al. Oligohydrosis and hyperthermia: pilot study of novel topiramate adverse effects. J Child Neurol. 2003;18(4):254-257.
38. de Carolis P, Magnifico F, Pierangeli G, et al. Transient hypohidrosis induced by topiramate. Epilepsia. 2003;44(7):974-976.
39. Levisohn PM. Safety and tolerability of topiramate in children. J Child Neurol. 2000;15(suppl 1):S22-S26.
40. Sen HA, O'Halloran HS, Lee WB. Topiramate-induced acute myopia and retinal striae. Arch Ophthalmol. 2001;119(5):775-777.
41. Medeiros FA, Zhang XY, Bernd AS, Weinreb RN. Angle-closure glaucoma associated with ciliary body detachment in patients using topiramate. Arch Ophthalmol. 2003;121(2):282-285.
42. Keates E, Clark T. Acute myopia and secondary angle closure glaucoma: a rare ocular syndrome in topiramate treated patients. Neurology. 2002;58(suppl 3):A422.
43. Uldall P, Bulteau C, Pedersen SA, Dulac O, Lyby K. Tiagabine adjunctive therapy in children with refractory epilepsy: a single-blind dose escalating study. Epilepsy Res. 2000;42(2-3):159-168.
44. Shinnar S. Tiagabine. Semin Pediatr Neurol. 1997:4(1):24-33.
45. Knake S, Hamer HM, Schomburg U, Oertel WH, Rosenow F. Tiagabine-induced absence status in idiopathic generalized epilepsy. Seizure. 1999;8(5):314-317.
46. Kellinghaus C, Dziewas R, Ludemann P. Tiagabine-related non-convulsive status epilepticus in partial epilepsy: three case reports and a review of the literature. Seizure. 2002;11(4):243-249.
47. Glauser TA, Pellock JM, Bebin EM, et al. Efficacy and safety of levetiracetam in children with partial seizures: an open-label trial. Epilepsia. 2002;43(5):518-524.
48. French J. Use of levetiracetam in special populations. Epilepsia. 2001;42(suppl 4):40-43.
49. Cohen J. Levetiracetam monotherapy for primary generalized epilepsy. Seizure. 2003;12(3):150-153.
50. Lagae L, Buyse G, Deconinck A, Ceulemans B. Effect of levetiracetam in refractory childhood epilepsy syndromes. Eur J Paediatr Neurol. 2003;7(3):123-128.
51. Lukyanetz EA, Shkryl VM, Kostyuk PG. Selective blockade of N-type calcium channels by levetiracetam. Epilepsia. 2002;43(1):9-18.
52. Rigo JM, Hans G, Nguyen L, et al. The anti-epileptic drug levetiracetam reverses the inhibition by negative allosteric modulators of neuronal GABA- and glycine-gated currents. Br J Pharmacol. 2002;136(5):659-672.
53. Leppik IE. The place of levetiracetam in the treatment of Epilepsy. Epilepsia. 2001;42(suppl 4):44-45.
54. Radtke RA. Pharmacokinetics of levetiracetam. Epilepsia. 2001;42(suppl 4):24-27.
55. Glauser TA, Pellock JM. Zonisamide in pediatric epilepsy: review of the Japanese experience. J Child Neurol. 2002;17(2):87-96.
56. Reigle SC, Gaillard WD, Pearl PL, Weinstein SL, Krohn K, Conry JA. Progressive myoclonic epilepsy (PME): response of seizures to zonisamide. Abstract presented at: American Epilepsy Society Annual Meeting; November 30-December 5, 2001; Philadelphia, PA.
57. Mullin P, Stern. JM, Delgado-Escueta AV, Eliashiv D. Effectiveness of open-label zonisamide in juvenile myoclonic epilepsy. Abstract presented at American Epilepsy Society Annual Meeting; November 30-December 5, 2001; Philadelphia, PA.
58. Knudsen JF, Thambi LR, Kapcala LP, Racoosin JA. Oligohydrosis and fever in pediatric patients treated with zonisamide. Pediatr Neurol. 2003;28(3):184-189.
59. Borusiak P, Korn-Merker E, Holert N, Boenigk HE. Oxcarbazepine in treatment of childhood epilepsy: as survey of 46 children and adolescents. J Epilepsy. 1998;11(6):355-360.
60. Glauser TA, Nigro M, Sachdeo R, et al. Adjunctive therapy with oxcarbazepine in children with partial seizures. Neurology. 2000; 54(12):2237-2244.
61. Gaily E, Granstrom ML, Liukkonen E. Oxcarbazepine in the treatment of early childhood epilepsy. J Child Neurol. 1997;12(8):496-498.
62. Holtmann M, Krause M, Opp J, Tokarzewski M, Korn-Merker E, Boenigk HE. Oxcarbazepine-induced hyponatremia and the regulation of serum sodium after replacing carbamazepine with oxcarbazepine in children. Neuropediatrics. 2002;33(6):298-300.
63. Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs. 2002;16(10):669-694.
64. Leppik IE, Schmidt D. Consensus statement on compliance in epilepsy. Epilepsy Res Suppl. 1988;1:179-182.